Clinical Center, Department of Laboratory Medicine, National Institutes of Health, Bethesda, Maryland.
Prism Health Dx Inc, Austin, Texas.
JAMA Cardiol. 2020 May 1;5(5):540-548. doi: 10.1001/jamacardio.2020.0013.
IMPORTANCE: Low-density lipoprotein cholesterol (LDL-C), a key cardiovascular disease marker, is often estimated by the Friedewald or Martin equation, but calculating LDL-C is less accurate in patients with a low LDL-C level or hypertriglyceridemia (triglyceride [TG] levels ≥400 mg/dL). OBJECTIVE: To design a more accurate LDL-C equation for patients with a low LDL-C level and/or hypertriglyceridemia. DESIGN, SETTING, AND PARTICIPANTS: Data on LDL-C levels and other lipid measures from 8656 patients seen at the National Institutes of Health Clinical Center between January 1, 1976, and June 2, 1999, were analyzed by the β-quantification reference method (18 715 LDL-C test results) and were randomly divided into equally sized training and validation data sets. Using TG and non-high-density lipoprotein cholesterol as independent variables, multiple least squares regression was used to develop an equation for very low-density lipoprotein cholesterol, which was then used in a second equation for LDL-C. Equations were tested against the internal validation data set and multiple external data sets of either β-quantification LDL-C results (n = 28 891) or direct LDL-C test results (n = 252 888). Statistical analysis was performed from August 7, 2018, to July 18, 2019. MAIN OUTCOMES AND MEASURES: Concordance between calculated and measured LDL-C levels by β-quantification, as assessed by various measures of test accuracy (correlation coefficient [R2], root mean square error [RMSE], mean absolute difference [MAD]), and percentage of patients misclassified at LDL-C treatment thresholds of 70, 100, and 190 mg/dL. RESULTS: Compared with β-quantification, the new equation was more accurate than other LDL-C equations (slope, 0.964; RMSE = 15.2 mg/dL; R2 = 0.9648; vs Friedewald equation: slope, 1.056; RMSE = 32 mg/dL; R2 = 0.8808; vs Martin equation: slope, 0.945; RMSE = 25.7 mg/dL; R2 = 0.9022), particularly for patients with hypertriglyceridemia (MAD = 24.9 mg/dL; vs Friedewald equation: MAD = 56.4 mg/dL; vs Martin equation: MAD = 44.8 mg/dL). The new equation calculates the LDL-C level in patients with TG levels up to 800 mg/dL as accurately as the Friedewald equation does for TG levels less than 400 mg/dL and was associated with 35% fewer misclassifications when patients with hypertriglyceridemia (TG levels, 400-800 mg/dL) were categorized into different LDL-C treatment groups. CONCLUSIONS AND RELEVANCE: The new equation can be readily implemented by clinical laboratories with no additional costs compared with the standard lipid panel. It will allow for more accurate calculation of LDL-C level in patients with low LDL-C levels and/or hypertriglyceridemia (TG levels, ≤800 mg/dL) and thus should improve the use of LDL-C level in cardiovascular disease risk management.
重要性:低密度脂蛋白胆固醇(LDL-C)是心血管疾病的一个关键标志物,通常通过 Friedewald 或 Martin 方程进行估算,但在 LDL-C 水平较低或高甘油三酯血症(甘油三酯[TG]水平≥400mg/dL)患者中,计算 LDL-C 的准确性较低。
目的:为 LDL-C 水平较低和/或高甘油三酯血症的患者设计更准确的 LDL-C 方程。
设计、设置和参与者:对 1976 年 1 月 1 日至 1999 年 6 月 2 日期间在国立卫生研究院临床中心就诊的 8656 名患者的 LDL-C 水平和其他脂质测量数据进行了分析,使用 β-量化参考方法(18715 个 LDL-C 测试结果)进行了分析,并将其随机分为大小相等的训练和验证数据集。使用 TG 和非高密度脂蛋白胆固醇作为自变量,采用多元最小二乘法回归法开发了极低密度脂蛋白胆固醇方程,然后将其用于 LDL-C 的第二个方程。使用内部验证数据集和多个外部数据集(β-量化 LDL-C 结果[ n=28715]或直接 LDL-C 测试结果[ n=252888])对方程进行了测试。统计分析于 2018 年 8 月 7 日至 2019 年 7 月 18 日进行。
主要结果和测量指标:通过各种准确性测量(相关系数[R2]、均方根误差[RMSE]、平均绝对差[MAD])评估计算的和通过β量化测量的 LDL-C 水平之间的一致性,并评估在 LDL-C 治疗阈值为 70、100 和 190mg/dL 时患者的错误分类百分比。
结果:与β量化相比,新方程比其他 LDL-C 方程更准确(斜率为 0.964;RMSE=15.2mg/dL;R2=0.9648;与 Friedewald 方程相比:斜率为 1.056;RMSE=32mg/dL;R2=0.8808;与 Martin 方程相比:斜率为 0.945;RMSE=25.7mg/dL;R2=0.9022),特别是对于高甘油三酯血症患者(MAD=24.9mg/dL;与 Friedewald 方程相比:MAD=56.4mg/dL;与 Martin 方程相比:MAD=44.8mg/dL)。新方程可以准确计算 TG 水平高达 800mg/dL 的患者的 LDL-C 水平,与 Friedewald 方程在 TG 水平低于 400mg/dL 时一样准确,并且当将高甘油三酯血症(TG 水平为 400-800mg/dL)患者分为不同的 LDL-C 治疗组时,错误分类的患者减少了 35%。
结论和相关性:与标准脂质组相比,新方程可以由临床实验室轻松实施,而且不会增加任何成本。它将能够更准确地计算 LDL-C 水平较低和/或高甘油三酯血症(TG 水平,≤800mg/dL)患者的 LDL-C 水平,从而应改善 LDL-C 水平在心血管疾病风险管理中的应用。
J Am Coll Cardiol. 2022-2-15
Eur Heart J Cardiovasc Pharmacother. 2023-2-2
Arterioscler Thromb Vasc Biol. 2025-8-14
Diagnostics (Basel). 2025-7-31
Front Endocrinol (Lausanne). 2025-7-17
J Clin Med. 2025-7-14
J Clin Lipidol. 2025-6-24
Adv Clin Exp Med. 2018-3
Curr Opin Endocrinol Diabetes Obes. 2018-4
World J Cardiol. 2017-2-26
J Clin Lab Anal. 2017-5